RxSight (RXST) Non-Current Deferred Tax Liability (2022 - 2023)
RxSight's (RXST) quarterly Non-Current Deferred Tax Liability came in at $646000.0 in Q4 2023, down 44.45% on a YoY basis from $1.2 million in Q4 2022, and down 44.45% quarter-over-quarter from $1.2 million in Q4 2022.
Powered by 
Analysis
RxSight (RXST) Non-Current Deferred Tax Liability (2022 - 2023) Analysis & Trends
RxSight (RXST) has reported Non-Current Deferred Tax Liability for 2 consecutive years, with $646000.0 the latest figure, recorded in Q4 2023.
- For the quarter ending Q4 2023, Non-Current Deferred Tax Liability fell 44.45% year-over-year to $646000.0; the trailing twelve-month figure through Dec 2023 stood at $646000.0 (down 44.45% YoY), and the FY2023 full-year result was $646000.0, down 44.45% from the prior year.
- Non-Current Deferred Tax Liability fell to $646000.0 in Q4 2023 per RXST's latest filing, from $1.2 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.2 million in Q4 2022 and bottomed at $646000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn |
| 10 | RxSight | 265.13 Mn | -139.12 Mn | - |